Journal article

Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia

Norelle L Sherry, Sarah L Baines, Benjamin P Howden

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | ELSEVIER SCIENCE BV | Published : 2018

Abstract

Avibactam (AVI) is a novel β-lactamase inhibitor active against class A, class C and some class D β-lactamases. In combination with ceftazidime, AVI may be useful for the treatment of infections due to Gram-negative bacteria producing carbapenemases from these classes; however, susceptibility data for some of the less common carbapenemases are limited. To assess the in vitro activity of ceftazidime/avibactam (CZA), a panel of 50 diverse carbapenemase-producing Gram-negative bacteria collected from clinical samples in Victoria, Australia, containing KPC, GES, SME, OXA-23 and OXA-48-like carbapenemases were tested for susceptibility to CZA using the broth microdilution (BMD), Etest and disk di..

View full abstract

Grants

Awarded by National Health and Medical Research Council Practitioner Fellowship


Funding Acknowledgements

This work was funded by AstraZeneca, which provided the avibactam, Etests and antibiotic disks for testing. AstraZeneca's rights to ceftazidime/avibactam were acquired by Pfizer in December 2016. The funders had no role in study design, data collection or interpretation. NLS and SLB are supported by Australian Government Research Training Program Scholarships. BPH is supported by a National Health and Medical Research Council Practitioner Fellowship [GNT1105905].